Table 1.
Clinicopathological characteristics of different subtypes of lung adenocarcinoma (n = 1244)
| Total | N0 (n = 789) | N1/N2 (n = 455) | p value | HR (95 % CI) | |
|---|---|---|---|---|---|
| Gender | |||||
| Male | 560 (45.0 %) | 327 (41.4 %) | 233 (51.2 %) | 0.001 | 1.282 (1.108–1.483) |
| Female | 684 (55.0 %) | 462 (58.6 %) | 222 (48.8 %) | ||
| Age | |||||
| < Average | 598 (48.1 %) | 360 (45.6 %) | 238 (52.3 %) | 0.023 | 1.185 (1.023–1.372) |
| ≥ Average | 646 (51.9 %) | 429 (54.4 %) | 217 (47.7 %) | ||
| Smoking status | |||||
| Former/current | 403 (32.4 %) | 225 (28.5 %) | 178 (39.1 %) | <0.001 | 1.340 (1.159–1.553) |
| Never | 841 (67.6 %) | 564 (71.5 %) | 277 (60.9 %) | ||
| Tumor locationa | |||||
| LUL | 330 (26.5 %) | 193 (24.5 %) | 137 (30.1 %) | 0.033 | 0.838 (0.717–0.979) |
| LLL | 200 (16.1 %) | 119 (15.1 %) | 81 (17.8 %) | 0.208 | 0.885 (0.734–1.066) |
| RUL | 406 (32.6 %) | 274 (34.7 %) | 132 (29.0 %) | 0.038 | 1.186 (1.006–1.397) |
| RML | 103 (8.3 %) | 64 (8.1 %) | 39 (8.6 %) | 0.777 | 0.963 (0.743–1.248) |
| RLL | 231 (18.6 %) | 150 (19.0 %) | 81 (17.8 %) | 0.597 | 1.053 (0.868–1.277) |
| LVI | |||||
| Yes | 203 (16.3 %) | 35 (4.4 %) | 168 (36.9 %) | <0.001 | 3.003 (2.674–3.378) |
| No | 1041 (83.7 %) | 754 (95.6 %) | 287 (63.1 %) | ||
| Differentiation | |||||
| Well | 169 (13.6 %) | 153 (19.4 %) | 16 (3.5 %) | <0.001 | 0.232 (0.145–0.372) |
| Moderate | 714 (57.4 %) | 492 (62.4 %) | 222 (48.8 %) | <0.001 | 0.707 (0.612–0.818) |
| Poor | 361 (29.0 %) | 144 (18.3 %) | 217 (47.7 %) | <0.001 | 2.232 (1.946–2.558) |
| Tumor size (cm) | |||||
| < 3 | 756 (60.8 %) | 572 (72.5 %) | 184 (40.4 %) | <0.001 | 2.283 (1.965–2.646) |
| ≥ 3 | 488 (39.2 %) | 217 (27.5 %) | 271 (59.6 %) | ||
| Predominant subtype | |||||
| L | 158 (12.7 %) | 154 (19.5 %) | 4 (0.9 %) | <0.001 | 0.061 (0.023–0.161) |
| A | 598 (48.1 %) | 211 (46.4 %) | 387 (49.0 %) | 0.363 | 0.935 (0.806–1.082) |
| P | 170 (13.7 %) | 98 (12.4 %) | 72 (15.8 %) | 0.092 | 1.188 (0.979–1.441) |
| M | 68 (5.5 %) | 35 (4.4 %) | 33 (7.3 %) | 0.035 | 1.353 (1.046–1.748) |
| S | 171 (13.7 %) | 62 (7.9 %) | 109 (24.0 %) | <0.001 | 1.976 (1.715–2.278) |
| IMA | 72 (5.8 %) | 48 (6.1 %) | 24 (5.3 %) | 0.556 | 0.907 (0.648–1.267) |
| Minor components | |||||
| L | 109 (8.8 %) | 94 (11.9 %) | 15 (3.3 %) | <0.001 | 0.355 (0.221–0.571) |
| A | 196 (15.8 %) | 123 (15.6 %) | 73 (16.0 %) | 0.832 | 1.021 (0.838–1.247) |
| P | 178 (14.3 %) | 97 (12.3 %) | 81 (17.8 %) | 0.008 | 1.297 (1.083–1.553) |
| M | 105 (8.4 %) | 49 (6.2 %) | 56 (12.3 %) | <0.001 | 1.522 (1.252–1.852) |
| S | 210 (16.9 %) | 103 (13.1 %) | 107 (23.5 %) | <0.001 | 1.513 (1.292–1.773) |
| IMA | 62 (5.0 %) | 34 (4.3 %) | 28 (6.2 %) | 0.150 | 1.250 (0.941–1.661) |
p value, HR, and 95 % CI were calculated using the Chi square test and Fisher’s exact test
HR hazard ratio, CI confidence interval, LUL left upper lobe, LLL left lower lobe, RUL right upper lobe, RML right middle lobe, RLL right lower lobe, LVI lymphovascular invasion, L lepidic, A acinar, P papillary, M micropapillary, S solid, IMA invasive mucinous adenocarcinoma
aWhen adding the percentage of this category together, a number more than 100 % may be obtained as some tumors occurred in more than one lobe